Prenetics Reaffirms 2025 Revenue Guidance of Up to $100 Million and Projects IM8 Revenue to Reach $200 Million in 2026

Reuters
2025/11/10
Prenetics Reaffirms 2025 Revenue Guidance of Up to $100 Million and Projects IM8 Revenue to Reach $200 Million in 2026

Prenetics Global Ltd. has reaffirmed its full-year 2025 revenue guidance, projecting total revenues of $90 to $100 million. The company expects its IM8 business unit to contribute $60 million in revenue for the year. For the fourth quarter of 2025, Prenetics has provided revenue guidance of $28 million for IM8, representing a 63% increase quarter-over-quarter compared to the third quarter of 2025. Looking ahead to 2026, IM8's full-year revenue is expected to reach between $180 and $200 million, with a target of approximately $25 million in monthly revenue or $300 million in annual recurring revenue $(ARR)$ by the end of 2026. This outlook follows a significant surge in business performance, as Prenetics reported a 567.7% year-over-year increase in total revenue to $23.6 million for the third quarter of 2025, and a 631.2% rise in gross profit to $14.0 million over the same period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prenetics Global Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10